PL2379057T3 - Preparaty fenylefryny o poprawionej stabilności - Google Patents

Preparaty fenylefryny o poprawionej stabilności

Info

Publication number
PL2379057T3
PL2379057T3 PL09795623T PL09795623T PL2379057T3 PL 2379057 T3 PL2379057 T3 PL 2379057T3 PL 09795623 T PL09795623 T PL 09795623T PL 09795623 T PL09795623 T PL 09795623T PL 2379057 T3 PL2379057 T3 PL 2379057T3
Authority
PL
Poland
Prior art keywords
improved stability
phenylephrine
formulations
phenylephrine formulations
stability
Prior art date
Application number
PL09795623T
Other languages
English (en)
Inventor
Timothy Dungan
Brian Warrington
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2379057T3 publication Critical patent/PL2379057T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL09795623T 2008-12-19 2009-12-11 Preparaty fenylefryny o poprawionej stabilności PL2379057T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13939108P 2008-12-19 2008-12-19
EP09795623.9A EP2379057B1 (en) 2008-12-19 2009-12-11 Phenylephrine formulations with improved stability
PCT/US2009/067618 WO2010080339A1 (en) 2008-12-19 2009-12-11 Phenylephrine formulations with improved stability

Publications (1)

Publication Number Publication Date
PL2379057T3 true PL2379057T3 (pl) 2013-12-31

Family

ID=42111353

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09795623T PL2379057T3 (pl) 2008-12-19 2009-12-11 Preparaty fenylefryny o poprawionej stabilności

Country Status (8)

Country Link
US (2) US20110237616A1 (pl)
EP (1) EP2379057B1 (pl)
KR (1) KR20110102344A (pl)
CA (1) CA2747411A1 (pl)
DK (1) DK2379057T3 (pl)
MX (1) MX2011006567A (pl)
PL (1) PL2379057T3 (pl)
WO (1) WO2010080339A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130627B2 (en) * 2008-12-19 2018-11-20 GlaxoSmithKine Consumer Healthcare S.A. Phenylephrine formulations with improved stability
US20150366823A1 (en) * 2013-02-06 2015-12-24 Hermes Arzneimittel Gmbh Pharmaceutical compositions incorporating low-dose drugs
WO2015137829A1 (en) * 2014-03-12 2015-09-17 Angeles Relinda G Stable and palatable liquid pharmaceutical composition of phenylephrine and a maleate salt of an antihistamine
WO2015193485A1 (en) 2014-06-20 2015-12-23 Hermes Arzneimittel Gmbh Taste-masked oral pharmaceutical composition
US10086026B2 (en) * 2016-06-27 2018-10-02 Uwais M. Syed Combined herbal and pharmaceutical composition and method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003009834A1 (en) * 2000-08-17 2003-02-06 Battey Alyce S Oral delivery of pharmaceuticals via encapsulation
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
US20070196496A1 (en) * 2002-04-16 2007-08-23 Michael Farber Delivery systems for functional ingredients
WO2006064327A1 (en) 2004-12-13 2006-06-22 Mcneil-Ppc, Inc. Compositons and methods for stabilizing active pharmaceutical ingredients
AU2005333081B2 (en) * 2005-06-17 2010-06-24 Aft Pharmaceuticals Limited Novel pharmaceutical composition and its use in a method for treatment of patients with upper respiratory mucosal congestion
GB2443793B (en) * 2006-04-05 2010-12-01 Reckitt Benckiser Healthcare Product, method of manufacture and use
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
US8323695B2 (en) * 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine

Also Published As

Publication number Publication date
US20110237616A1 (en) 2011-09-29
DK2379057T3 (da) 2013-10-14
WO2010080339A4 (en) 2010-09-02
WO2010080339A1 (en) 2010-07-15
EP2379057A1 (en) 2011-10-26
KR20110102344A (ko) 2011-09-16
US20160015815A1 (en) 2016-01-21
EP2379057B1 (en) 2013-07-17
CA2747411A1 (en) 2010-07-15
MX2011006567A (es) 2011-08-03

Similar Documents

Publication Publication Date Title
TWI370466B (en) Trensformer structure
ZA201103926B (en) Stable sulfoximine-insecticide compositions
PL2918172T3 (pl) Połączenia środków kontroli biologicznej i fungicydów
GB0815435D0 (en) Formulations
EP2329016A4 (en) MODIFIED BETA GLUCOSIDASES WITH INCREASED STABILITY
ZA201006679B (en) Orally-disintergrating solid preparation
GB2459691B (en) Formulations
GB0823269D0 (en) Formulations
GB0821789D0 (en) Formulations
GB0806216D0 (en) Interconnector
EP2307021A4 (en) FORMULATIONS
EP2309553A4 (en) INTERCONNECTOR
GB0806978D0 (en) Novel formulations
GB0822633D0 (en) Formulation
PL2379057T3 (pl) Preparaty fenylefryny o poprawionej stabilności
ZA201004772B (en) Novel formulation
GB0814376D0 (en) Formulation
GB0801122D0 (en) Vaccine composition
GB0921378D0 (en) Formulations
GB0916030D0 (en) Formulations
GB0822171D0 (en) Temisartan formulations
GB0813041D0 (en) Ruler
PL2328593T3 (pl) Kardioplegiczny preparat
GB0916106D0 (en) Formulations
GB0823486D0 (en) Formulations